Erin Wilson
Stock Analyst at Morgan Stanley
(1.79)
# 3,187
Out of 4,944 analysts
22
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $26 → $28 | $21.32 | +31.33% | 7 | May 13, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $145.74 | +402.26% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $155.00 | +148.39% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $190.23 | +39.31% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $468.00 | -56.20% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $176.29 | +41.81% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $17.81 | +113.36% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $21.78 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $484.79 | -29.66% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.64 | +3,192.68% | 4 | Nov 14, 2017 |
Rapid7
May 13, 2025
Maintains: Equal-Weight
Price Target: $26 → $28
Current: $21.32
Upside: +31.33%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $145.74
Upside: +402.26%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $155.00
Upside: +148.39%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $190.23
Upside: +39.31%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $468.00
Upside: -56.20%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $176.29
Upside: +41.81%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $17.81
Upside: +113.36%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $21.78
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $484.79
Upside: -29.66%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.64
Upside: +3,192.68%